Doctors continue to heavily prescribe the cholesterol drug Vytorin, though there is no proof that it helps prolong life or prevent heart attacks.

Doctors continue to heavily prescribe the cholesterol drug Vytorin, though six years after its approval there is still no proof that the drug helps patients live longer or avoid heart attacks.

A growing number of children are taking drugs for a wide range of chronic conditions related to childhood obesity.

The settlement of a patent dispute over the blockbuster cholesterol drug will delay the release of generic versions in the United States until 2011.

The settlement of a patent dispute over the blockbuster cholesterol drug will delay the release of generic versions in the United States until 2011.

The settlement of a patent dispute over the blockbuster cholesterol drug will delay the release of generic versions in the U.S. until 2011.

An experimental cholesterol drug being developed by Merck & Company was rejected by the Food and Drug Administration, the company said on Monday.

Isis Pharmaceuticals will delay submitting final results from a late-stage study of its cholesterol drug after United States health regulators asked for additional cancer-related data from two preclinical trials.